Compass Point downgraded Horizon Technology (HRZN) to Sell from Neutral with a $10 price target after Evelo Biosciences (EVLO) announced its Phase 2 clinical study with EDP2939 in moderate psoriasis did not achieve the study’s primary endpoint.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRZN:
- Compass Point ups Horizon Technology to Neutral on positive 12-month return
- Avalo Therapeutics eliminates $35M debt
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue